Nancy Harrison has over 25 years financing and building companies in the biotech industry. Since 2020, Nancy has been a Venture Partner with Amplitude Ventures, a full-stack life sciences venture capital firm focused on creating, building, and growing world-class Canadian precision medicine companies. From 2008 until 2017, Nancy was the President and co-founder of MSI Methylation Sciences Inc., a company with a focus on CNS.

Prior to MSI, Ms. Harrison was a Partner of Ventures West Management Inc. building the company from $70 million under management to $850 million. As one of the most experienced life sciences investors in the Canadian venture capital industry, she was instrumental in Ventures West’s involvement in the sector and with companies such as Angiotech Pharmaceuticals Inc., AnorMed Inc., Xenon Pharmaceuticals, Sembiosys Genetics Inc., Caprion Pharmaceuticals Inc., Celator Technologies Inc., and Alder Biopharmaceuticals. Ms Harrison has an undergraduate degree in Engineering from Queen’s University and an MBA from McGill University.